瑞加诺生心肌灌注显像用于肺病患者冠心病评估:五例病例系列
本文报告了五例中重度肺部疾病患者使用瑞加诺生心肌灌注显像评估冠心病的病例系列。瑞加诺生是唯一被批准用于心肌灌注显像的选择性腺苷A2A受体激动剂,所有病例均提供了有价值的风险评估和治疗优化信息,虽全部出现呼吸困难但耐受良好,无严重不良事件或支气管痉挛。
要点
- 瑞加诺生可用于中重度肺病患者的心肌灌注显像负荷试验。
- 五例患者均出现呼吸困难,但无需干预,无支气管痉挛或严重不良事件。
- 该检查为肺病合并冠心病患者的风险评估和治疗优化提供了有价值信息。
核心结论
- 瑞加诺生心肌灌注显像在中重度肺病患者中耐受良好,未发生支气管痉挛或严重不良事件。
- 该检查为肺病患者的冠心病风险评估和治疗优化提供了有价值的信息。
研究设计与样本
- 病例系列研究,纳入五例中重度肺部疾病患者,包括需肺减容手术和肺移植者。
主要发现
- 所有五例患者使用瑞加诺生后均出现呼吸困难,但无需干预治疗。
- 无严重不良事件或支气管痉挛发生。
- 所有病例的瑞加诺生心肌灌注显像均提供了有价值的风险评估和治疗优化信息。
关键数值与推荐
- 瑞加诺生是唯一被批准用于心肌灌注显像血管扩张的选择性腺苷A2A受体激动剂。
- 腺苷因支气管收缩风险在呼吸系统疾病患者中禁用。
临床怎么用
- 对中重度肺病合并冠心病待评估患者,可考虑使用瑞加诺生进行心肌灌注显像负荷试验。
- 检查中出现的呼吸困难通常无需干预,但需监测。
局限性
- 本文为五例病例系列,样本量小,未设对照。
- 大型随机试验未纳入最严重呼吸系统疾病患者,本文结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronary artery disease (CAD) is a leading cause of death and morbidity globally. Myocardial perfusion scintigraphy (MPS) is commonly used for the diagnosis of CAD, necessitating hyperaemia achieved either by physical exertion or by pharmacological stress, most commonly through use of a coronary arteriolar dilator. This is challenging in patients with respiratory conditions because exercise may be submaximal and adenosine is contraindicated because of the risk of bronchoconstriction. Regadenoson is the only selective adenosine A2A receptor agonist approved as a vasodilator in MPS. The risk of bronchospasm with regadenoson has been investigated in large, randomised trials; however, patients with the most severe respiratory conditions were not included. In this case series, we present the use of regadenoson MPS in five patients with moderate-to-severe lung conditions, including patients requiring lung volume reduction surgery and lung transplant. In all cases, regadenoson MPS provided valuable information for risk assessment and treatment optimisation. Although dyspnoea occurred in all patients, regadenoson was well tolerated without serious adverse events or bronchospasm; in no case was intervention required to treat dyspnoea.
引用
- Reyes E, Richard Underwood S. Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases. J Nucl Cardiol. 2019. PMID: 31797320. doi:10.1007/s12350-019-01956-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。